National Cancer Institute


Expert-reviewed information summary about the treatment of adult Hodgkin lymphoma.

This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about the treatment of adult Hodgkin lymphoma. It is intended as a resource to inform and assist clinicians who care for cancer patients. It does not provide formal guidelines or recommendations for making health care decisions.

This summary is reviewed regularly and updated as necessary by the PDQ Adult Treatment Editorial Board, which is editorially independent of the National Cancer Institute (NCI). The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH).

Adult Hodgkin Lymphoma Treatment

General Information About Adult Hodgkin Lymphoma (HL)

Incidence and Mortality

Estimated new cases and deaths from HL in the United States in 2017:

  • New cases: 8,260.
  • Deaths: 1,070.

More than 75% of all newly diagnosed patients with adult HL can be cured with combination chemotherapy and/or radiation therapy. National mortality has fallen more rapidly for adult HL than for any other malignancy over the last 5 decades.

Prognosis and Survival Factors

Prognosis for a given patient depends on several factors. The most important factors are the presence or absence of systemic symptoms, the stage of disease, presence of large masses, and the quality and suitability of the treatment administered. Other important factors are age, sex, erythrocyte sedimentation rate, extent of abdominal involvement, hematocrit, and absolute number of nodal sites of involvement.

HL is the main cause of death over the first 15 years after treatment. By 15 to 20 years after therapy, the cumulative mortality from a second malignancy will exceed the cumulative mortality from HL.

Related Summaries

Other PDQ summaries containing information related to Hodgkin lymphoma include the following:

  • AIDS-Related Lymphoma Treatment
  • Childhood Hodgkin Lymphoma Treatment

Cellular Classification of Adult HL

Pathologists currently use the World Health Organization (WHO) modification of the Revised European-American Lymphoma (REAL) classification for the histologic classification for adult Hodgkin lymphoma (HL).

WHO/REAL classification

  • Classical HL.
    • Nodular sclerosis HL.
    • Mixed-cellularity HL.
    • Lymphocyte depletion HL.
    • Lymphocyte-rich classical HL.
  • Nodular lymphocyte–predominant HL.

Among 10,019 patients who underwent central expert pathology review for the German Hodgkin Study Group, 84 patients (<1%) were identified as having lymphocyte-depleted classical HL. These patients present with more advanced-stage HL and usually with B symptoms.

Nodular Lymphocyte–Predominant HL

Nodular lymphocyte–predominant HL (NLPHL) is a clinicopathologic entity of B-cell origin that is distinct from classic HL. The typical immunophenotype for lymphocyte-predominant disease is CD15-, CD20+, CD30-, CD45+, while the profile for classic HL is CD15+, CD20-, CD30+, CD45-. Patients with lymphocyte-predominant disease have earlier-stage disease, longer survival, and fewer treatment failures than those with classic HL. Despite a usually favorable prognosis, there is a tendency for histologic transformation to diffuse large B-cell lymphoma or T-cell–rich large B-cell lymphoma in approximately 10% of patients by 10 years. This propensity of NLPHL to transform to aggressive B-cell lymphoma underscores the importance of long-term follow-up and re-biopsy at relapse. Lymphocyte-predominant HL is usually diagnosed in asymptomatic young males with cervical or inguinal lymph nodes but usually without mediastinal involvement. Based on retrospective analyses spanning several decades and because of the rarity of this histology, limited-field radiation therapy is the most common treatment approach for patients with early-stage disease.

The REAL Classification of Lymphoid Neoplasms proposed separating NLPHL (CD15-, CD20+, CD30-) from lymphocyte-rich classical HL (CD15+, CD20-, CD30+), on the basis of these immunophenotypic differences. The largest retrospective report of 426 cases showed no significant difference in clinical response or outcome to standard therapies for these two subgroups.[] Of interest, with a median follow-up of 7 to 8 years, more patients died of treatment-related toxic effects (acute and long-term) than from Hodgkin recurrence. Limitation of radiation dose and fields and avoidance of leukemogenic chemotherapeutic agents, along with watchful waiting policies, should be investigated for these subgroups. For patients with advanced-stage NLPHL, chemotherapy regimens designed for patients with non-HLs may be preferred, based on two retrospective reviews and a phase II study.[]

Rituximab had a 100% response rate in a phase II trial of 39 previously untreated and relapsed NLPHL patients. With a median follow-up of 9.8 years, the median PFS was 3.0 years for patients who received rituximab induction only and 5.6 years for patients who received rituximab induction plus rituximab maintenance.[] With induction only, 9 of 23 patients relapsed with an aggressive B-cell lymphoma.

Stage Information for Adult HL

Clinical staging for patients with Hodgkin lymphoma (HL) includes a history, physical examination, laboratory studies (including sedimentation rate), and thoracic and abdominal/pelvic computerized tomographic (CT) scans with or without positron emission tomography (PET).

PET scans combined with CT scans have become the standard imaging for clinical staging. A prospective, multinational study of 260 newly diagnosed patients with advanced-stage HL obtained PET scans at baseline and after two cycles (four doses) of doxorubicin plus bleomycin plus vinblastine plus dacarbazine (ABVD); with a median follow-up of 2.2 years, the 2-year progression-free survival (PFS) was 12.8% with a positive PET scan after two cycles and 95% with a negative PET scan after two cycles ( < .0001). In a prospective trial of BEACOPP-based therapy—includes the drugs bleomycin, etoposide, doxorubicin hydrochloride, cyclophosphamide, vincristine sulfate, procarbazine, and prednisone—for previously untreated patients with advanced-stage HL, patients with residual abnormalities measuring 2.5 cm or more received a PET scan at the end of therapy. A negative PET scan predicted no progression or relapse within 1 year for 94% of patients (confidence interval, 91%–97%). Whether consolidation with radiation therapy can be omitted for PET-negative patients must await overall survival data at 5 years. Only further prospective studies that compare a PET response–adapted strategy versus standard therapy without alteration can assess whether improved outcomes can be achieved by altering the therapeutic strategy based on PET scan results. In two prospective randomized trials encompassing 1,739 patients with clinical stage I or II HL, acute relapse rates were lower with combined modality therapy, even for patients with a negative interim PET scan. These trials do not support using interim PET scans to determine the value of radiation therapy for early-stage disease. Both studies showed that patients with early-stage disease and a negative PET scan after two or three cycles of ABVD had a very good prognosis (PFS exceeding 90% at 3 years in one of the studies) with or without consolidation radiation therapy. Neither of these studies has been followed long enough (>10 years) to assess long-term toxicities or treatment-related mortality.

Bone marrow involvement occurs in 5% of patients; biopsy may be indicated in the presence of constitutional B symptoms or anemia, leukopenia, or thrombocytopenia. In a retrospective review and meta-analysis of 955 patients in nine studies, fewer than 2% of patients with a positive bone marrow biopsy had only stage I or II disease on PET-CT scans; omission of the bone marrow biopsy for PET-CT–designated early-stage patients did not change treatment selection. Staging laparotomy is no longer recommended and should be considered only when the results will allow substantial reduction in treatment. Staging laparotomy should not be done in patients who require chemotherapy. If the laparotomy is required for treatment decisions, the risks of potential morbidity should be considered. The staging classification that is currently used for HL was adopted in 1971 at the Ann Arbor Conference with some modifications 18 years later from the Cotswolds meeting.

Subclassification of stage

Stages I, II, III, and IV adult HL can be subclassified into A and B categories: B for those with defined general symptoms and A for those without B symptoms. The B designation is given to patients with any of the following symptoms:

  • Unexplained loss of more than 10% of body weight in the 6 months before diagnosis.
  • Unexplained fever with temperatures above 38°C.
  • Drenching night sweats. (Refer to the PDQ summary on Hot Flashes and Night Sweats for more information.)

The designation E is used when well-localized extranodal lymphoid malignancies arise in or extend to tissues beyond, but near, the major lymphatic aggregates. Stage IV refers to disease that is diffusely spread throughout an extranodal site, such as the liver. If pathologic proof of involvement of one or more extralymphatic sites has been documented, the symbol for the site of involvement, followed by a plus sign (+), is listed.

Current practice is to assign a clinical stage (CS) based on the findings of the clinical evaluation and a pathologic stage (PS) based on the findings of invasive procedures.

For example, a patient who has disease in the chest and neck, systemic symptoms, and a negative lymphangiogram might be found at laparotomy to have involvement of the spleen, liver, and bone marrow. Thus, the precise stage of such a patient would be CS IIB, PS IVB (S+)(H+)(M+).

The American Joint Committee on Cancer (AJCC) has designated staging using the Ann Arbor classification system to define adult Hodgkin lymphoma.

Massive mediastinal disease has been defined by the Cotswolds meeting as a thoracic ratio of maximum transverse mass diameter of 33% or more of the internal transverse thoracic diameter measured at the T5/6 intervertebral disc level on chest radiography. Some investigators have designated a lymph node mass measuring 10 cm or more in greatest dimension as massive disease. Other investigators use a measurement of the maximum width of the mediastinal mass divided by the maximum intrathoracic diameter.

Many investigators and many new clinical trials employ a clinical staging system that divides patients into four major groups that are also useful for the practicing physician:

  • Early favorable: Clinical stage I or II without any risk factors.
  • Early unfavorable: Clinical stage I or II with one or more of the following risk factors:
    • Large mediastinal mass (>33% of the thoracic width on the chest x-ray, ≥10 cm on CT scan).
    • Extranodal involvement.
    • Elevated erythrocyte sedimentation rate (>30 mm/h for B stage, >50 mm/h for A stage).
    • Three or more lymph node areas' involvement.
    • B symptoms.
  • Advanced: For patients with advanced-stage HL, the International Prognostic Factors Project has developed an International Prognostic Index with a prognostic score that is based on the following seven adverse factors:
    • Albumin level of <4.0 g/dL.
    • Hemoglobin level of <10.5 g/dL.
    • Male sex.
    • Age of ≥45 years.
    • Stage IV disease.
    • White blood cell (WBC) count of ≥15,000/mm.
    • Absolute lymphocytic count of <600/mm or a lymphocyte count that was <8% of the total WBC count.

Treatment Option Overview for Adult HL

Drug combinations described in this section include the following:

  • ABVD: doxorubicin, bleomycin, vinblastine, and dacarbazine.
  • BEACOPP: bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone.
  • MOPP: mechlorethamine, vincristine, procarbazine, and prednisone.

After initial clinical staging for Hodgkin lymphoma (HL), patients with obvious stage III or IV disease, bulky disease (defined as a 10 cm mass or mediastinal disease with a transverse diameter exceeding 33% of the transthoracic diameter), or the presence of B symptoms will require combination chemotherapy with or without additional radiation therapy.

Patients with nonbulky stage IA or IIA disease are considered to have clinical early-stage disease. These patients are candidates for chemotherapy, combined modality therapy, or radiation therapy alone. Staging laparotomy is no longer recommended because it may not alter management and does not enhance ultimate outcome. When chemotherapy alone or combined modality therapy is applied, laparotomy is not required.

Radiation Therapy

In adult HL, the appropriate dose of radiation alone is 25 Gy to 30 Gy to clinically uninvolved sites and 35 Gy to 44 Gy to regions of initial nodal involvement. These recommendations are often modified in pediatric or advanced-staged adult patients who also receive chemotherapy. Treatment is usually delivered to the neck, chest, and axilla (mantle field) and then to an abdominal field to treat para-aortic nodes and the spleen (splenic pedicle). In some patients, pelvic nodes are treated with a third field. The three fields constitute total nodal radiation therapy. In some cases, the pelvic and para-aortic nodes are treated in a single field called an inverted Y. In patients with a favorable prognosis, treatment of the pelvic lymph nodes is frequently omitted, since fertility can be preserved without affecting relapse-free survival.

Second Malignancies

Acute nonlymphocytic leukemia may occur in patients treated with combined modality therapy or with combination chemotherapy alone, especially with increasing exposure to alkylating agents. At 10 years after therapy with regimens containing MOPP, the risk of acute myelogenous leukemia (AML) is approximately 3%, with the peak incidence occurring 5 to 9 years after therapy. The risk of acute leukemia at 10 years following therapy with ABVD appears to be less than 1%. A population-based study of more than 35,000 survivors during a 30-year time span identified 217 patients who developed AML; the excess absolute risk is significantly higher (9.9 vs. 4.2 after 1984, < .001) for older patients (i.e., >35 years at diagnosis) versus younger survivors.

An increase in second solid tumors has also been observed, especially cancers of the lung, breast, thyroid, bone/soft tissue, stomach, esophagus, colon and rectum, uterine cervix, head and neck, and mesothelioma. These tumors occur primarily after radiation therapy or with combined modality treatment, and approximately 75% occur within radiation ports. At a 15-year follow-up, the risk of second solid tumors (cumulative incidence of a second cancer) is approximately 13%; at a 20-year follow-up, the risk is approximately 17%; at a 25-year follow-up, the risk is approximately 22%; and at a 40-year follow-up, the risk is approximately 48%. In a cohort of 18,862 5-year survivors from 13 population-based registries, the younger patients had elevated risks for breast, colon, and rectal cancer for 10 to 25 years before the age when routine screening would be recommended in the general population. Even with involved-field doses of 15 Gy to 25 Gy, sarcomas, breast cancers, and thyroid cancers occurred with similar incidence in young patients receiving higher-dose radiation.

Lung cancer is seen with increased frequency, even after chemotherapy alone, and the risk of this cancer is increased with cigarette smoking. In a retrospective Surveillance, Epidemiology, and End Results (SEER) analysis, stage-specific survival was decreased by 30% to 60% in HL survivors compared with patients with de novo non-small cell lung cancer. Breast cancer is seen with increased frequency after radiation therapy or combined modality therapy. The risk appears greatest for women treated with radiation before age 30 years and especially close to menarche, and the incidence increases substantially after 15 years of follow-up. In two case control studies of 479 patients who developed breast cancer after therapy for HL, cumulative absolute risks for developing breast cancer were calculated as a function of radiation therapy dose and the use of chemotherapy. With a 30-year to 40-year follow-up, cumulative absolute risks of breast cancer with exposure to radiation range from 8.5% to 39.6%, depending on the age at diagnosis. A family history of breast cancer or ovarian cancer does not confer a greater increased risk than that of radiation therapy for one of these cohorts. These cohort studies show a continued increase in cumulative excess risk of breast cancer beyond 20 years of follow-up.

In a nested case control study and subsequent cohort study, patients who received both chemotherapy and radiation therapy had a statistically significant lower risk of developing breast cancer than those treated with radiation therapy alone. Reaching early menopause with less than 10 years of intact ovarian function appeared to account for the reduction in risk among patients who received combined modality therapy. Reduction of radiation volume also decreased the risk of breast cancer after HL. The risk of non-HL is also increased, but this risk is not clearly related to type or extent of treatment.

Several studies suggest that splenic-field radiation therapy and splenectomy increase the risk of a treatment-related second cancer. Late effects after autologous stem cell transplantation that is given for failure of induction chemotherapy include second malignancies, hypothyroidism, hypogonadism, herpes zoster, depression, and cardiac disease.

Adverse Effects of Therapy

A toxic effect that is primarily related to chemotherapy is infertility, usually after MOPP-containing or BEACOPP-containing regimens; After six to eight cycles of BEACOPP, most men had testosterone levels within normal range; however, among women younger than 30 years, 82% recovered menses (mostly within 12 months) but only 45% of women older than 30 years recovered menses. ABVD appears to spare long-term testicular and ovarian function.

Late complications primarily related to radiation therapy include hypothyroidism and cardiac disease, which may persist through to 25 years after first treatment. The absolute excess risk of fatal cardiovascular disease ranges from 11.9 to 48.9 per 10,000 patient years and is mostly attributable to fatal myocardial infarction (MI). The use of subcarinal blocking did not reduce the incidence of fatal MI in a retrospective review, perhaps because of the exposure of the proximal coronary arteries to radiation. In a cohort of 7,033 HL patients, MI mortality risk persisted through to 25 years after first treatment with supradiaphragmatic radiation therapy (dependent on the details of treatment planning), doxorubicin, or vincristine. HL patients treated with mediastinal radiation compared with a normal-matched population have been reported to be at increased risk with the use of cardiac procedures.

Impairment of pulmonary function may occur as a result of mantle-field radiation therapy; this impairment is not usually clinically evident, and recovery in pulmonary testing often occurs after 2 to 3 years. Pulmonary toxic effects from bleomycin as used in ABVD are seen in older patients (especially those older than 40 years). Avascular necrosis of bone has been observed in patients treated with chemotherapy and is most likely related to corticosteroid therapy.

Bacterial sepsis may occur rarely after splenectomy performed during staging laparotomy for HL; it is much more frequent in children than in adults. The Advisory Committee on Immunization Practices recommends that all patients with HL, whether or not they have had a splenectomy, should be immunized with type b conjugate, meningococcal, and pneumococcal vaccines at least 1 week before treatment. Some investigators recommend reimmunization with all three vaccines 2 years after completion of treatment and with pneumococcal vaccine every 6 years thereafter.

Fatigue is a commonly reported symptom of patients who have completed chemotherapy. In a case-control study design, a majority of HL survivors reported significant fatigue lasting for more than 6 months after therapy compared with age-matched controls. Quality-of-life questionnaires given to 5,306 patients on German Hodgkin Study Group trials showed that 20% of patients complained of severe fatigue 5 years after therapy, and those patients had significantly increased problems with employment and financial stability.

Recommendations for screening for secondary malignancies or follow-up of long-term survivors are consensus based rather than derived from randomized trials.

Patients older than 60 years with HL may experience more treatment-related morbidity and mortality; maintaining dose intensity of standard chemotherapy may be difficult. Alternative therapies have been proposed for elderly patients, but no randomized trials have been conducted with these regimens. A series of 27 previously untreated patients older than 60 years, judged by the investigator to be in too poor a condition to undergo chemotherapy, received brentuximab. A 92% overall response rate and 73% complete remission rate were reported.[]

Recommendations for posttreatment follow-up are not evidence based, but a variety of opinions have been published for high-risk patients who present with advanced-stage disease or for patients who achieve less-than-complete remission by positron emission tomography–computed tomography scans at the end of therapy.

Early Favorable HL

Drug combinations described in this section include the following:

  • ABV: doxorubicin, bleomycin, and vinblastine.
  • ABVD: doxorubicin, bleomycin, vinblastine, and dacarbazine (1 cycle = 1 mo of therapy).
  • AV: doxorubicin and vinblastine.
  • AVD: doxorubicin, vinblastine, and dacarbazine.
  • MOPP-ABV: mechlorethamine, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vincristine.

Patients are designated as having early favorable Hodgkin lymphoma (HL) if they have clinical stage I or stage II disease and no adverse risk factors. Adverse risk factors include the following:

  • B symptoms (fever ≥38°C, soaking night sweats, weight loss ≥10% within 6 mo). (Refer to the PDQ summary on Hot Flashes and Night Sweats for more information.)
  • Extranodal disease.
  • Bulky disease (≥10 cm or >33% of the chest diameter on chest x-ray).
  • Three or more sites of nodal involvement.
  • Sedimentation rate ≥50 mm/h.

Historically, radiation therapy alone had been the primary treatment for patients with early favorable HL, often after confirmatory negative staging laparotomy. A randomized, prospective trial involving 542 patients with early favorable HL compared MOPP-ABV for three cycles plus involved-field radiation therapy (IF-XRT) with subtotal nodal radiation; with a median follow-up of 7.7 years, combined modality was favored in terms of 5-year event-free survival (98% vs. 74%, < .001) and 10-year overall survival (OS) (97% vs. 92%, = .001).[] The late mortality from solid tumors, especially in the lung, breast, gastrointestinal tract, and connective tissue, and from cardiovascular disease makes radiation therapy a less attractive option for the best-risk patients, who have the highest probability of cure and long-term survival. Recent clinical trials have focused on regimens with chemotherapy and IF-XRT or with chemotherapy alone.

A randomized, prospective trial from the National Cancer Institute of Canada involving 123 patients with early favorable HL compared ABVD for four to six cycles with subtotal nodal radiation; with a median follow-up of 11.3 years, no difference was observed in event-free survival (89% vs. 86%; = .64) or in OS (98% vs. 98%; = 0.95).[]

In a randomized study from the Milan Cancer Institute of patients with clinical early-stage HL, 4 months of ABVD followed by either IF-XRT or extended-field radiation therapy (EF-XRT) showed similar OS and freedom-from-progression with a 10-year median follow-up, but the study had inadequate statistical power to determine noninferiority of IF-XRT versus EF-XRT.[]

The German Hodgkin Lymphoma Study Group (GHSG) randomly assigned 1,190 patients with early favorable HL to the following:

  • Two cycles of ABVD plus 30 Gy of IF-XRT.
  • Two cycles of ABVD plus 20 Gy of IF-XRT.
  • Four cycles of ABVD plus 30 Gy of IF-XRT.
  • Four cycles of ABVD plus 20 Gy of IF-XRT.

With a 7.6-year median follow-up, no differences were observed in freedom-from-progression (97%) or OS (98%) for all four groups.[]

The GHSG study (HD 13) compared reduced chemotherapy schedules while maintaining IF-XRT at 30 Gy: two cycles of ABVD, two cycles of ABV, two cycles of AVD, or two cycles of AV among 1,502 patients. After 5 years, freedom from treatment failure was significantly worse when dacarbazine, bleomycin, or both were omitted. This trial suggests that ABVD remains the standard therapy when given in four doses with radiation therapy for early-stage favorable disease..

A specialized approach to therapy can be taken when patients with nonbulky lymphocyte–predominant disease presenting in unilateral high neck (above the thyroid notch) or epitrochlear locations require only IF-XRT after clinical staging. A retrospective report of 426 cases of lymphocyte-predominant HL (including the so-called nodular lymphocyte–predominant and lymphocyte-rich classical subtypes) showed that more patients died of treatment-related toxicity (both acute and long term) than from recurrence of HL.[] Limitation of radiation dose and radiation fields and avoidance of leukemogenic chemotherapeutic agents, along with watchful waiting policies, should be investigated for these subgroups. Patients with nonbulky nodular sclerosing disease presenting in the anterior mediastinum only after clinical staging also do well with mantle radiation alone.

Treatment options include the following:

  • ABVD for four to six cycles.
  • ABVD for two cycles plus IF-XRT (20 Gy or 30 Gy).
  • Radiation therapy alone in special circumstances.

Current Clinical Trials

Check the list of NCI-supported cancer clinical trials that are now accepting patients with stage I adult Hodgkin lymphoma and stage II adult Hodgkin lymphoma. The list of clinical trials can be further narrowed by location, drug, intervention, and other criteria.

General information about clinical trials is also available from the NCI website.

Early Unfavorable HL

Drug combinations described in this section include the following:

  • ABVD: doxorubicin, bleomycin, vinblastine, and dacarbazine (1 cycle = 1 mo of therapy).
  • AV: doxorubicin and vinblastine.
  • BEACOPP: bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone.
  • COPP/ABVD: cyclophosphamide, vincristine, procarbazine, prednisone/doxorubicin, bleomycin, vinblastine, and dacarbazine.
  • MOPP/ABV: mechlorethamine, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vincristine.

Patients are designated as having early unfavorable Hodgkin lymphoma (HL) if they have clinical stage I or stage II disease and one or more of the following risk factors:

  • B symptoms (fever ≥38°C, soaking night sweats, weight loss ≥10% within 6 mo).
  • Extranodal disease.
  • Bulky disease (≥10 cm or >33% of the chest diameter on chest x-ray).
  • Three or more sites of nodal involvement.
  • Sedimentation rate of ≥50 mm/h.

Patients with early unfavorable HL showed relapse rates greater than 30% at 5 years with radiation therapy alone, prompting evaluation of chemotherapy plus involved-field radiation therapy (IF-XRT) versus chemotherapy alone. The late mortality from solid tumors, especially in the lung, breast, gastrointestinal tract, and connective tissue, and from cardiovascular disease makes radiation therapy a less attractive option unless therapeutic benefits exceed the long-term complications.

A randomized, prospective trial from the National Cancer Institute of Canada (NCIC) involving 276 patients with early unfavorable HL compared ABVD for four to six cycles with ABVD for two cycles plus extended-field radiation therapy (EF-XRT); with a median follow-up of 11.3 years, the freedom-from-progression favored combined modality therapy (86% vs. 94%; = .006), but the overall survival (OS) was better for ABVD alone (92% vs. 81%; = .04).[] The trend toward a worse survival for the combined modality arm was attributed to excess secondary malignancies and cardiovascular deaths. In this trial, the extended-field radiation used higher doses and significantly larger exposure to body sites than are employed in current practice.

A randomized study from the Southwest Oncology Group of clinically staged patients (no laparotomy) compared subtotal lymphoid radiation with 3 months of AV followed by subtotal lymphoid radiation therapy; the combined modality arm showed superior failure-free survival (94% vs. 81%; < .001) but not OS at 3.3 years' median follow-up.[]

In a randomized study from the Milan Cancer Institute of patients with clinical early-stage HL, 4 months of ABVD followed by either IF-XRT or EF-XRT showed similar OS and freedom-from-progression with 10 years' median follow-up, but the study had inadequate statistical power to determine noninferiority of IF-XRT versus EF-XRT.[] Similarly, in a randomized study from the German Hodgkin Lymphoma Study Group (GHSG) of more than 1,000 patients with early unfavorable HL, 4 months of COPP plus ABVD followed by IF-XRT versus EF-XRT showed equivalent OS and freedom-from-treatment failure (FFTF) with 5 years' median follow-up.[] Another randomized study of 996 patients with early unfavorable HL also showed no difference in OS and event-free survival at 10 years, comparing four to six cycles of MOPP-ABV plus IF-XRT versus the same chemotherapy plus subtotal nodal radiation therapy.[]

In the HD11 trial, the GHSG randomly assigned 1,395 patients with early unfavorable HL to the following:

  • Four cycles of ABVD plus 30 Gy of IF-XRT.
  • Four cycles of ABVD plus 20 Gy of IF-XRT.
  • Four cycles of BEACOPP plus 30 Gy of IF-XRT.
  • Four cycles of BEACOPP plus 20 Gy of IF-XRT.

With a 6.8 year median follow-up no differences were observed in OS (93%–96%) for all four groups.[] In the arms of the study with 30 Gy of IF-XRT, there was no difference in FFTF between BEACOPP and ABVD ( = .65), but a significant difference in favor of BEACOPP was seen for FFTF when 20 Gy of IF-XRT was used ( = .02).[]

In the HD14 trial, the GHSG randomly assigned 1,528 patients with early unfavorable HL to either four cycles of ABVD plus 30 Gy of IF-XRT or two cycles of escalated BEACOPP followed by two cycles of ABVD plus 30 Gy of IF-XRT. With a median follow-up of 43 months, no difference was observed in OS.[]

A prospective, randomized trial from the European Organization for Research and Treatment of Cancer and Groupe d'Etudes de Lymphomes de L'Adulte of 808 patients with early unfavorable HL compared the following:

  • Four cycles of ABVD plus 30 Gy of IF-XRT.
  • Six cycles of ABVD plus 30 Gy of IF-XRT.
  • Four cycles of BEACOPP plus 30 Gy of IF-XRT.

With a 64-month median follow-up, in a preliminary report in abstract form, no differences were observed in event-free survival (89%–92%; = .38) or OS (91%–96%; = .98).[]

In summary, these randomized trials support the use of ABVD for four cycles with 20 Gy to 30 Gy IF-XRT. Could the radiation therapy be omitted to minimize late morbidity and mortality from secondary solid tumors and from cardiovascular disease? The NCIC study is the only trial to address this question in patients with early unfavorable HL; although four to six cycles of ABVD alone has improved OS compared with a combined modality approach, the use of EF-XRT in the combined modality arm is excessive by current standards, and late effects will be magnified with these larger fields. In addition, chemotherapy alone was 8% worse in freedom-from-progression compared with the combined modality approach.

How can we balance an improvement in freedom-from-progression using radiation therapy with chemotherapy against late morbidity and mortality from late effects? Randomized studies with or without IF-XRT would be required, but no such studies are currently under way. An indirect comparison for using ABVD alone is that the 94% OS seen for early unfavorable patients in the NCIC study at 11 years is equivalent to the survival seen in the GHSG's [NCT00002561], [NCT01399931], and HD11 trials using combined modality therapy at 11 years. A Cochrane meta-analysis of 1,245 patients in five randomized, clinical trials suggested improved survival for combined modality therapy versus chemotherapy alone (HR, 0.40; 95% CI, 0.27–0.61). However, the NCIC study does demonstrate a 92% OS for ABVD alone at a median follow-up of 11.3 years. This would support the use of ABVD for patients with early unfavorable disease. Long-term follow-up, which would account for late toxicities and deaths from combined modality therapy, will not be forthcoming from these trials.

Patients with bulky disease (≥10 cm) or massive mediastinal involvement were excluded from most of the aforementioned trials. Based on historical comparisons to chemotherapy or radiation therapy alone, these patients currently receive combined modality therapy.[]

Treatment options include the following:

  • Four to six cycles of ABVD.
  • Four cycles of ABVD plus IF-XRT (20 Gy–30 Gy).

Current Clinical Trials

Check the list of NCI-supported cancer clinical trials that are now accepting patients with stage I adult Hodgkin lymphoma and stage II adult Hodgkin lymphoma. The list of clinical trials can be further narrowed by location, drug, intervention, and other criteria.

General information about clinical trials is also available from the NCI website.

Advanced HL

Drug combinations described in this section include the following:

  • ABVD: doxorubicin, bleomycin, vinblastine, and dacarbazine.
  • BEACOPP: bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone.
  • MOPP/ABV hybrid: mechlorethamine, vincristine, procarbazine, prednisone/doxorubicin, bleomycin, and vinblastine.
  • Stanford V: doxorubicin, vinblastine, mechlorethamine, etoposide, vincristine, bleomycin, and prednisone.

In multiple prospective trials and a meta-analysis, ABVD therapy for 6 to 8 months remains the standard of care for patients with advanced Hodgkin lymphoma (HL), with equivalent overall survival (OS) when compared with other regimens (i.e., BEACOPP, escalated BEACOPP, Stanford V, and MOPP-ABV).[]

Three prospective, randomized trials did not show a benefit in OS from the addition of consolidative radiation therapy to chemotherapy for patients with advanced-stage disease.[] In a meta-analysis of 1,740 patients treated on 14 different trials, no improvement was observed in 10-years' OS for patients with advanced-stage HL who received combined modality therapy versus chemotherapy alone.[] The German Hodgkin Lymphoma Study Group HD15 trial showed that a negative positive–emission tomographic (PET) scan after BEACOPP induction therapy was highly predictive for a good outcome even with omission of consolidative radiation therapy (negative predictive value for PET was 94% [95% confidence interval, 91%–97%]). No survival advantage is known for the use of radiation consolidation for patients with massive mediastinal disease and advanced stage disease, though differences exist in sites of first relapse.

Treatment options include the following:

  • ABVD for six to eight cycles.

Current Clinical Trials

Check the list of NCI-supported cancer clinical trials that are now accepting patients with stage III adult Hodgkin lymphoma and stage IV adult Hodgkin lymphoma. The list of clinical trials can be further narrowed by location, drug, intervention, and other criteria.

General information about clinical trials is also available from the NCI website.

Recurrent Adult HL

Recommendations for posttreatment follow-up are not evidence based, but a variety of opinions have been published for high-risk patients who present with advanced-stage disease or for patients who achieve less-than-complete remission by positron emission tomography–computed tomography (PET-CT) scans at the end of therapy. For patients with a negative PET-CT scan at the end of therapy, routine scans are not advised; opportunistic scanning is applied when patients present with suspicious symptoms, physical findings, or laboratory tests.

Among 6,840 patients enrolled in German Hodgkin Study Group trials, with a median follow-up of 10.3 years, 141 patients relapsed after 5 years, compared with 466 patients who relapsed within 5 years. Treatment-related adverse effects and late relapses may occur even beyond 20 years of follow-up.

Patients who experience a relapse after initial wide-field, high-dose radiation therapy have a good prognosis. Combination chemotherapy results in 10-year disease-free survival (DFS) and overall survival (OS) rates of 57% to 81% and 57% to 89%, respectively. For patients who experience a relapse after initial combination chemotherapy, prognosis is determined more by the duration of the first remission than by the specific induction or salvage combination chemotherapy regimen. Patients whose initial remission after chemotherapy was longer than 1 year (late relapse) have long-term survival with salvage chemotherapy of 22% to 71%. Patients whose initial remission after chemotherapy was shorter than 1 year (early relapse) do much worse and have long-term survival rates of 11% to 46%.

Because of CD30 expression on malignant Reed-Sternberg cells of Hodgkin Lymphoma (HL), but limited expression on normal cells, CD30 is a target for therapy. Brentuximab vedotin is a chimeric antibody directed against CD30, which is linked to the microtubule-disrupting agent, monomethyl auristatin E. For relapsing patients, response rates around 75% are seen with complete remissions around 30% to 50% and median progression-free survival (PFS) of 4 to 8 months.[] A series of 27 previously untreated patients older than 60 years, judged by the investigator to be in poor condition and unable to undergo chemotherapy, received brentuximab. A 92% overall response rate and 73% complete remission rate were reported.[] Successful treatment with brentuximab for relapsed patients has been reported with a response rate of 60%.[]

Patients who relapse after initial combination chemotherapy can undergo reinduction with the same or another chemotherapy regimen followed by high-dose chemotherapy and autologous bone marrow or peripheral stem cell or allogeneic bone marrow rescue. This therapy has resulted in a 3- to 4-year DFS rate of 27% to 48%. Patients who are responsive to reinduction chemotherapy may have a better prognosis. In a retrospective review of 105 patients, those older than 60 years fared better with a combination of chemotherapy and salvage radiation therapy than with the use of intensified transplant consolidation.[]

Two randomized trials have compared aggressive conventional chemotherapy versus high-dose chemotherapy with autologous hematopoietic stem cell transplantation for relapsed chemosensitive HL. Both trials show improvement in freedom from treatment failure at 3 years for the transplantation arm (75% vs. 45% and 55% vs. 34%, respectively); but no difference was observed in OS.[] A Cochrane meta-analysis also concluded that autologous stem cell transplantation after reinduction chemotherapy improves relapse-free survival by 20% to 30% over chemotherapy alone but without an OS benefit.[]

In two retrospective reviews of patients who underwent autologous bone marrow transplantation (ABMT) for relapsed or refractory disease, a comparison was made of those who received involved-field radiation therapy (IF-XRT) for residual masses after high-dose therapy versus no further treatment. Those who received IF-XRT had improved PFS. Normalization of fluorine F 18-fludeoxyglucose PET-CT scans after reinduction therapy predicted a much better outcome after stem cell transplantation, with an event-free survival rate of 80% versus 29% in one phase II trial.[]

For 329 patients at high risk of residual HL after stem cell transplant, the double-blind trial [NCT01100502] evaluated brentuximab vedotin versus placebo; the median PFS of 42.9 months for the brentuximab group was better than the 24.1 months for the control group (hazard ratio, 0.57; 95% confidence interval [CI], 0.40–0.81; = .0013).[]

The use of human leukocyte antigen-matched sibling marrow (allogeneic transplantation) results in a lower relapse rate, but the benefit may be offset by increased toxic effects. Reduced-intensity conditioning for allogeneic stem cell transplantation is also under clinical evaluation.

The anti-PD1 monoclonal antibody nivolumab, one of the new immune checkpoint inhibitors, has shown an overall response rate of 65% to 87% and a complete response rate of 16% to 28%, with durations usually exceeding 1 year for heavily pretreated, relapsed patients.[]

A phase II trial reported a response rate higher than 50% for bendamustine in relapsing patients.[] For patients with recurrent disease after ABMT, weekly vinblastine therapy has provided palliation with minimal toxic effects.[]

For the small subgroup of patients with only limited nodal recurrence following initial chemotherapy, radiation therapy with or without additional chemotherapy may provide long-term survival for about 50% of these highly selected patients.

Patients who do not respond to induction chemotherapy (about 10%–20% of all presenting patients) have less than a 10% survival rate at 8 years. For these patients, high-dose chemotherapy and autologous bone marrow or peripheral stem cell or allogeneic bone marrow rescue are under clinical evaluation. These trials have resulted in a 3- to 5-year DFS rate of 17% to 48%.

Current Clinical Trials

Check the list of NCI-supported cancer clinical trials that are now accepting patients with recurrent adult Hodgkin lymphoma. The list of clinical trials can be further narrowed by location, drug, intervention, and other criteria.

General information about clinical trials is also available from the NCI website.

HL During Pregnancy

Introduction

Because Hodgkin lymphoma (HL) affects primarily young adults, most oncologists will eventually face the dilemma of how to provide therapy to a pregnant woman while minimizing the risk to the fetus. Treatment choice must be individualized, taking into consideration the mother’s wishes, the severity and pace of the HL, and the length of the remaining pregnancy. Since general guidelines can never substitute for clinical judgment, oncologists should be prepared to alter the initial plans when necessary.

Stage Information for HL During Pregnancy

To avoid exposure to ionizing radiation, magnetic resonance imaging is the preferred tool for staging evaluation. The presenting stage, clinical behavior, prognosis, and histologic subtypes of HL during pregnancy do not differ from those of nonpregnant women during their childbearing years. (Refer to the Stage Information for Adult Hodgkin Lymphoma (HL) section of this summary for more information.)

Treatment Option Overview for HL During Pregnancy

HL that is diagnosed in the first trimester of pregnancy does not constitute an absolute indication for therapeutic abortion. Each patient must be looked at individually to take into account the stage and rapidity of growth of the lymphoma and the patient's wishes. If the HL presents in early stage above the diaphragm and appears to be growing slowly, patients can be followed carefully with plans to induce delivery early and proceed with definitive therapy. Alternatively, these patients can receive radiation therapy with proper shielding. Investigators at MD Anderson Cancer Center reported no congenital abnormalities in 16 babies delivered after the mothers had received supradiaphragmatic radiation while shielding the uterus with five half-value layers of lead. Because of theoretical risks that the fetus might develop future malignancies from even minimal scattered radiation doses outside the radiation field, radiation therapy should be postponed, if possible, until after delivery.

Chemotherapy that is administered in the first trimester has been associated with congenital abnormalities in as many as 33% of infants. However, in one series, there were no adverse effects in 14 children of mothers who received a combination of mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) or a combination of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) during gestation, five of whom began treatment during the first trimester. Consequently, some women may opt to continue the pregnancy and agree to radiation therapy or chemotherapy if immediate treatment is required.

In the second half of pregnancy, most patients can be followed carefully and can postpone therapy until induction of delivery at 32 to 36 weeks. If chemotherapy is mandatory before delivery, such as for patients with symptomatic advanced stage disease, vinblastine alone (given at 6 mg/m² IV q 2 wk until induction of delivery) may be considered because it has never been associated with fetal abnormalities in the second half of pregnancy. Steroids are employed both for their antitumor effect and for hastening fetal pulmonary maturity. As an alternative, a short course of radiation therapy can be used before delivery in cases of respiratory compromise caused by the rapidly enlarging mediastinal mass. Combination chemotherapy with ABVD appears to be safe in the second half of pregnancy. If chemotherapy is required after the first trimester, many clinicians prefer the combination of drugs over single-agent drugs or radiation therapy.

A multicenter retrospective analysis of 40 patients described pregnancy termination in 3 patients, deferral of therapy to postpartum in 13 patients (median 30 wk gestation), and antenatal therapy applied to the remaining 24 patients (median 21 wk gestation, all done after the first trimester). With a median follow-up of 41 months, the 3-year progression-free survival (PFS) was 85%, and the overall survival (OS) was 97%, often using ABVD.[]

A retrospective analysis from MD Anderson of 39 patients described pregnancy termination in 3 patients, deferral of therapy to the postpartum period in 12 patients, and antenatal therapy in 24 patients. Two women miscarried after receiving doxorubicin-based chemotherapy in the first trimester. With a median follow-up of 68 months from diagnosis, the 5-year rate of PFS was 75%, and the OS rate was 82%. These rates did not differ between the antenatal and postpartum timing of therapy.[]

In one study, the 20-year survival rate of pregnant women with HL did not differ from the 20-year survival rate of nonpregnant women who were matched for similar stage of disease, age at diagnosis, and calendric year of treatment. The long-term effects on progeny after chemotherapy in utero are unknown, though present evidence tends to be reassuring. There is no evidence that a pregnancy after completion of therapy increases the relapse rate for patients in remission.

Key References for Adult HL

These references have been identified by members of the PDQ Adult Treatment Editorial Board as significant in the field of adult Hodgkin lymphoma treatment. This list is provided to inform users of important studies that have helped shape the current understanding of and treatment options for adult Hodgkin lymphoma. Listed after each reference are the sections within this summary where the reference is cited.

  • Canellos GP, Abramson JS, Fisher DC, et al.: Treatment of favorable, limited-stage Hodgkin's lymphoma with chemotherapy without consolidation by radiation therapy. J Clin Oncol 28 (9): 1611-5, 2010.[PUBMED Abstract]

    Cited in:

    • Early Favorable HL
    • Early Unfavorable HL
  • Chen R, Palmer JM, Thomas SH, et al.: Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma. Blood 119 (26): 6379-81, 2012.[PUBMED Abstract]

    Cited in:

    • Recurrent Adult HL
  • Eich HT, Diehl V, Görgen H, et al.: Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. J Clin Oncol 28 (27): 4199-206, 2010.[PUBMED Abstract]

    Cited in:

    • Early Unfavorable HL
  • Engert A, Plütschow A, Eich HT, et al.: Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med 363 (7): 640-52, 2010.[PUBMED Abstract]

    Cited in:

    • Early Favorable HL
  • Gallamini A, Hutchings M, Rigacci L, et al.: Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. J Clin Oncol 25 (24): 3746-52, 2007.[PUBMED Abstract]

    Cited in:

    • Stage Information for Adult HL
  • Hodgson DC, Gilbert ES, Dores GM, et al.: Long-term solid cancer risk among 5-year survivors of Hodgkin's lymphoma. J Clin Oncol 25 (12): 1489-97, 2007.[PUBMED Abstract]

    Cited in:

    • Treatment Option Overview for Adult HL
  • Meyer RM, Gospodarowicz MK, Connors JM, et al.: ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma. N Engl J Med 366 (5): 399-408, 2012.[PUBMED Abstract]

    Cited in:

    • Early Favorable HL
    • Early Unfavorable HL
  • Schmitz N, Pfistner B, Sextro M, et al.: Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet 359 (9323): 2065-71, 2002.[PUBMED Abstract]

    Cited in:

    • Recurrent Adult HL
  • Viviani S, Zinzani PL, Rambaldi A, et al.: ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned. N Engl J Med 365 (3): 203-12, 2011.[PUBMED Abstract]

    Cited in:

    • Advanced HL
  • von Tresckow B, Plütschow A, Fuchs M, et al.: Dose-intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German hodgkin study group HD14 trial. J Clin Oncol 30 (9): 907-13, 2012.[PUBMED Abstract]

    Cited in:

    • Early Unfavorable HL

Changes to This Summary (07/05/2017)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

Treatment Option Overview for Adult Hodgkin Lymphoma (HL)

Added text to state that quality-of-life questionnaires given to 5,306 patients on German Hodgkin Study Group trials showed that 20% of patients complained of severe fatigue 5 years after therapy, and those patients had significantly increased problems with employment and financial stability (cited Behringer et al. as reference 64).

Recurrent Adult HL

Added text to state that for patients with a negative positron emission tomography-computed tomography (PET-CT) scan at the end of therapy, routine scans are not advised; opportunistic scanning is applied when patients present with suspicious symptoms, physical findings, or laboratory tests.

Added text to state that among 6,840 patients enrolled in German Hodgkin Study Group trials, with a median follow-up of 10.3 years, 141 patients relapsed after 5 years, compared with 466 patients who relapsed within 5 years. Also added that treatment-related adverse effects and late relapses may occur even beyond 20 years of follow-up (cited Bröckelmann et al. as reference 5).

HL During Pregnancy

Added text to state that a retrospective analysis from MD Anderson of 39 patients described pregnancy termination in 3 patients, deferral of therapy to the postpartum period in 12 patients, and antenatal therapy in 24 patients. Also added that two women miscarried after receiving doxorubicin-based chemotherapy in the first trimester. With a median follow-up of 68 months from diagnosis, the 5-year rate of progression-free survival was 75%, the overall survival rate was 82%, and these rates did not differ between the antenatal and postpartum timing of therapy (cited Pinnix et al. as reference 17 and level of evidence 3iiiDiv).

This summary is written and maintained by the PDQ Adult Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ® - NCI's Comprehensive Cancer Database pages.

About This PDQ Summary

Purpose of This Summary

This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about the treatment of adult Hodgkin lymphoma. It is intended as a resource to inform and assist clinicians who care for cancer patients. It does not provide formal guidelines or recommendations for making health care decisions.

Reviewers and Updates

This summary is reviewed regularly and updated as necessary by the PDQ Adult Treatment Editorial Board, which is editorially independent of the National Cancer Institute (NCI). The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH).

Board members review recently published articles each month to determine whether an article should:

  • be discussed at a meeting,
  • be cited with text, or
  • replace or update an existing article that is already cited.

Changes to the summaries are made through a consensus process in which Board members evaluate the strength of the evidence in the published articles and determine how the article should be included in the summary.

The lead reviewer for Adult Hodgkin Lymphoma Treatment is:

  • Eric J. Seifter, MD (Johns Hopkins University)

Any comments or questions about the summary content should be submitted to Cancer.gov through the NCI website's Email Us. Do not contact the individual Board Members with questions or comments about the summaries. Board members will not respond to individual inquiries.

Levels of Evidence

Some of the reference citations in this summary are accompanied by a level-of-evidence designation. These designations are intended to help readers assess the strength of the evidence supporting the use of specific interventions or approaches. The PDQ Adult Treatment Editorial Board uses a formal evidence ranking system in developing its level-of-evidence designations.

Permission to Use This Summary

PDQ is a registered trademark. Although the content of PDQ documents can be used freely as text, it cannot be identified as an NCI PDQ cancer information summary unless it is presented in its entirety and is regularly updated. However, an author would be permitted to write a sentence such as “NCI’s PDQ cancer information summary about breast cancer prevention states the risks succinctly: [include excerpt from the summary].”

The preferred citation for this PDQ summary is:

PDQ® Adult Treatment Editorial Board. PDQ Adult Hodgkin Lymphoma Treatment. Bethesda, MD: National Cancer Institute. Updated . Available at: https://www.cancer.gov/types/lymphoma/hp/adult-hodgkin-treatment-pdq. Accessed . [PMID: 26389473]

Images in this summary are used with permission of the author(s), artist, and/or publisher for use within the PDQ summaries only. Permission to use images outside the context of PDQ information must be obtained from the owner(s) and cannot be granted by the National Cancer Institute. Information about using the illustrations in this summary, along with many other cancer-related images, is available in Visuals Online, a collection of over 2,000 scientific images.

Disclaimer

Based on the strength of the available evidence, treatment options may be described as either “standard” or “under clinical evaluation.” These classifications should not be used as a basis for insurance reimbursement determinations. More information on insurance coverage is available on Cancer.gov on the Managing Cancer Care page.

Contact Us

More information about contacting us or receiving help with the Cancer.gov website can be found on our Contact Us for Help page. Questions can also be submitted to Cancer.gov through the website’s Email Us.


A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
R
S
T
U
V
X
Y
Z
#
 
A
B
C
E
F
G
H
K
L
M
N
O
P
R
S
T
U
V
 
 
Manténgase informado con las últimas informaciones de OncoLink!   Suscribirse a OncoLink eNews
Ver nuestros archivos de boletines